Hematology Service, University Hospital La Fe. Valencia, Spain.
Expert Rev Hematol. 2011 Aug;4(4):381-98. doi: 10.1586/ehm.11.38.
The treatment of newly diagnosed multiple myeloma (MM) has evolved rapidly over recent years. The availability of new effective drugs with novel mechanisms of action, such as bortezomib, in the last decade have resulted in a new scenario expected to impact favorably on the outcome of MM patients. In the transplant and nontransplant setting, several randomized trials have shown that front-line treatment with bortezomib-based combinations are superior to conventional treatment and have allowed for a significant increase of complete response rate, with a positive impact on progression-free survival. Furthermore, this drug appears to be active in patients with high-risk disease and comorbidities. Thus, bortezomib-containing regimens are now considered as a new standard of care for newly diagnosed myeloma patients. In this article, we will attempt to overview the results of bortezomib when administered as a standard component of front-line therapy for MM patients.
近年来，新诊断多发性骨髓瘤（MM）的治疗方法迅速发展。在过去十年中，出现了许多新型有效药物，这些药物具有新型作用机制，如硼替佐米，这为 MM 患者的治疗结果带来了积极影响。在移植和非移植环境中，多项随机试验表明，采用硼替佐米为基础的联合方案进行一线治疗优于常规治疗，并显著提高了完全缓解率，对无进展生存期有积极影响。此外，该药似乎对高危疾病和合并症患者有效。因此，含硼替佐米的方案目前被认为是新诊断骨髓瘤患者的新标准治疗方案。本文将尝试概述硼替佐米作为 MM 患者一线治疗标准方案的治疗结果。
